Hsp70 peptide stimulating natural killer (nk) cell activity and uses thereof
AssigneeMultimmune GmbH
InventorGabriele Multhoff
Life of this patent
Estimating the term…
Abstract
The present invention relates to an immunostimulatory peptide derived from an Hsp70 protein and peptides comprising said immunostimulatory peptide. Furthermore the present invention pertains to polynucleotides encoding said peptide, vectors comprising said polynucleotides, fusion (poly)peptides comprising said peptide and compositions comprising said peptide. In addition the present invention relates to the use of said peptide, polynucleotide, vector or fusion (poly)peptide, for the preparation of pharmaceutical compositions for the treatment of diseases and for the stimulation of natural killer cell (NK cell) activity.
Claims16
A peptide comprising or having the following amino acid sequence TKDNNLLGRFELXG Wherein X is T or S
- or a fragment or derivative thereof.
The polynucleotide of claim 5 which is DNA.
A method of producing a immunostimulatory peptide comprising
- (a) mutating on the DNA or amino acid level a DNA molecule encoding or peptide comprising the sequence TKDNNLLGRFELXG, wherein X is T or S, in one or more nuclebtide or amino acid positions;
- (b) testing the proliferative response of NK cells to stimulation with IL-2 and/or IL18 together with the mutated peptide;
- (c) comparing the proliferative response of NK cells to IL-2 and/or IL-18 together with the mutated peptide to the proliferative response to IL-2 and/or IL-18 without the mutated peptide or with a peptide having the sequence recited in (a);
- (d) selecting a peptide comprising the mutated sequence Or a recombinant DNA molecule coding for a peptide comprising the mutated sequence, wherein said mutated peptide displays an increase in the proliferative response as compared to IL-2 and/or IL-18 without the mutated peptide or with a peptide having the sequence recited in (a) in step (c).
Dependencies are inferred from the claim text.